Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Mar 13;9(3):e019368.
doi: 10.1136/bmjopen-2017-019368.

Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2-17 years: systematic review and meta-analysis

Bruno Rodrigues Rosa  1 , Antonio José Ledo Alves da Cunha  1 , Roberto de Andrade Medronho  1
Affiliations
Meta-Analysis

Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2-17 years: systematic review and meta-analysis

Bruno Rodrigues Rosa et al. BMJ Open. .

Abstract

Background: Randomised controlled trials have evaluated the recombinant tetravalent dengue vaccine (CYD-TDV). However, individual results may have little power to identify differences among the populations studied.

Objective: To evaluate efficacy, immunogenicity and safety of CYD-TDV in the prevention of dengue in children aged 2-17 years.

Design: Systematic review and meta-analysis.

Data sources: MEDLINE (from 1950 to 5 December 2018), EMBASE (from 1947 to 5 December 2018) and Cochrane (from 1993 to 5 December 2018).

Eligibility criteria of studies: Randomised trials comparing efficacy, immunogenicity and safety of CYD-TDV with placebo or other vaccines for preventing dengue cases in children aged 2-17 years.

Outcome measures: Efficacy, immunogenicity and safety of CYD-TDV.

Study appraisal and methods: Calculations were made of relative risk (RR) and mean difference (MD) for dichotomous and continuous outcomes, respectively. All estimates were calculated considering a 95% CI estimate. A p<0.05 was considered statistically significant.

Results: Nine studies involving 34 248 participants were included. The overall efficacy of CYD-TDV was 60% (RR 0.40 (0.30 to 0.54)). Serotype-specific efficacy of the vaccine was 51% for dengue virus type-1 (DENV-1) (RR 0.49 (0.39 to 0.63)); 34% for DENV-2 (RR 0.66 (0.50 to 0.86)); 75% for DENV-3 (RR 0.25 (0.18 to 0.35)) and 77% for DENV-4 (RR 0.23 (0.15 to 0.34)). Overall immunogenicity (MD) of CYD-TDV was 225.13 (190.34 to 259.93). Serotype-specific immunogenicity was: DENV-1: 176.59 (123.36 to 229.83); DENV-2: 294.21 (181.98 to 406.45); DENV-3: 258.78 (146.72 to 370.84) and DENV-4: 189.35 (141.11 to 237.59). The most common adverse events were headache and pain at the injection site.

Limitations: The main limitation of this study was unclear or incomplete data.

Conclusions and implications of key findings: CYD-TDV is considered safe and able to partially protect children and adolescents against four serotypes of DENV for a 1-year period. Despite this, research should prioritise improvements in vaccine efficacy, thus proving higher long-term protection against all virus serotypes.

Prospero registration number: CRD42016043628.

Keywords: child; dengue; vaccine.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Study flow chart. CYD-TDV, recombinant tetravalent dengue vaccine.
Figure 2
Figure 2
Overall and serotype-specific DENV efficacy analysis. DENV, dengue virus; M-H, Mantel-Haenszel.
Figure 3
Figure 3
Overall and serotype-specific DENV immunogenicity analysis. CYD-TDV, recombinant tetravalent dengue vaccine; DENV, dengue virus; IV, inverse variance.
See this image and copyright information in PMC

References

    1. World Health Organization. Dengue: guidelines for diagnosis, treatment, prevention and control. World Health Organization, New edition, 2009. WHO/HTM/NTD/DEN/2009.1 Available at: http://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf/ (accessed 27 Sep 2015). - PubMed
    1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013;496:504–7. 10.1038/nature12060 - DOI - PMC - PubMed
    1. World Health Organization. Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses. World Health Organization, 2007. WHO/IVB/07.07 Available at: www.who.int/vaccines-documents/ (accessed 15 Jun 2014). - PubMed
    1. World Health Organization. Media Centre. Dengue and severe dengue. Fact sheet N°117, January 2012. Available at: http://www.who.int/mediacentre/factsheets/fs117/en/ (accessed 17 May 2014).
    1. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998;11:480–96. 10.1128/CMR.11.3.480 - DOI - PMC - PubMed

Substances